Clinical trial NCT04469556: Pancreatic Adenocarcinoma Signature Stratification for Treatment
Official title: Pancreatic Adenocarcinoma Signature Stratification for Treatment
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Pancreatic Cancer Metastatic
Pancreatic Ductal Adenocarcinoma
Advanced Pancreatic Cancer
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
Collaborators: name: Johns Hopkins University
name: Cold Spring Harbor Laboratory
name: Ontario Institute for Cancer Research
name: Dana-Farber Cancer Institute
name: Memorial Sloan Kettering Cancer Center
name: Stand Up To Cancer
First posted: 2020-07-14
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Approximately 150 patients will be randomized in a 1:1 ratio to receive one of the two standard of care regimens in patients with confirmed metastatic PDAC
Primary purpose: TREATMENT

Brief summary: This is a randomized multicentre phase II trial with a large translational component. The trial will evaluate the two standard chemotherapy regimens: modified folfirinox (mFFX) and gemcitabine/nab-paclitaxel (GA), in patients with untreated metastatic pancreatic ductal adenocarcinoma. Integrated into this phase II trial are a number of laboratory components including molecular profiling, patient derived organoid establishment, and drug testing sensitivity and other biomarkers.

Detailed description: The two chemotherapy regimens GA and mFFX remain standard treatment options without biomarkers to predict response. PASS-01 will for the first time explore progression free survival differences in the two standard backbone regimens used in the advanced setting. Biomarker driven strategies in pancreatic ductal adenocarcinoma (PDAC) are lacking, perhaps accounting for a large number of failed phase II studies. This study will evaluate two standard of care chemotherapy regimens, but will also explore high content molecular profiling, chemotherapy sensitivity signatures, GATA6 and other putative biomarkers as predictors of response to chemotherapy. In addition, the use of patient derived organoid models for personalized medicine in PDAC will continue to develop within this study.

Approximately 150 patients diagnosed with untreated metastatic pancreatic cancer will be randomized to either arm.

Eligibility criteria: Inclusion Criteria:

1. Patients must have a histological or radiological diagnosis of untreated metastatic PDAC at screening with histology subsequently confirmed prior to randomization.
2. Eligible histologic variants include adenocarcinoma or variants to include mucinous adenocarcinoma or adenosquamous carcinoma.
3. Patients with a history of prior or concurrent second primary malignancy whose natural history or treatment does not have the potential to interfere with the safety or primary endpoint efficacy assessment of the pancreas cancer should generally be eligible for enrollment in clinical trials.
4. Age ≥18 years.
5. Patient must have a tumor lesion that is amenable to a core needle biopsy.
6. Patients must be suitable for treatment with either mFFX and GA without contraindications to either regimen.
7. Eastern Cooperative Group (ECOG) performance status 0-1. (Karnofsky ≥70%).
8. Life expectancy of greater than 90 days, as judged by the investigator
9. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test and must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
10. Within 14 days of the proposed randomization date, patients must have normal organ and marrow function

Exclusion Criteria:

1. Patients who have received prior systemic treatment for PDAC, including treatment in the neoadjuvant or adjuvant setting. Prior surgery or palliative radiation is permitted.
2. Patients with histology other than pancreatic ductal adenocarcinoma. Those with adenosquamous are allowed. Acinar tumors and colloid are excluded.
3. Patients with one or more contraindications to tumor biopsy according to local institution's standard biopsy procedures.
4. Patients with known brain metastases are excluded from participation in this clinical study.
5. Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, inability to stop anticoagulation medication for a biopsy, or psychiatric illness/social situations that would limit compliance with study requirements.
6. Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
7. Patients with a known germline mutation in BRCA, PALB2 or other homologous Recombination Repair Deficiency (HRD) genes.
8. Patients who are pregnant or breastfeeding.
9. Use (including 'recreational use') of any illicit drugs or other substance abuse (including alcohol) that could potentially interfere with adherence to study procedures or requirements. \*Use of any illicit drugs or other substance abuse (including alcohol) are not screened in Canada using Toxicity testing. -

Primary outcomes:
measure: Progression free survival(PFS) in mFFX and GA arms pancreatic ductal adenocarcinoma (PDAC) in a randomized phase II trial.
timeFrame: 2-4 years
Secondary outcomes:
measure: ORR by RECIST 1.1 and duration of response in patients receiving mFFX or GA
timeFrame: 2-4 years
measure: Overall survival (OS) associated with mFFX or GA profiles, signatures and pharmacotyping
timeFrame: 2-4 years
measure: GATA6 as a biomarker of response to mFFX or GA
timeFrame: 2-4 years
measure: • Concordance between organoid transcriptomic profiles (RNAseq) and patient transcriptomic profiles (descriptive statistics)
timeFrame: 2-4 years
measure: • Concordance between chemotherapy sensitivity signature predictions and response to first line treatment (descriptive statistics).
timeFrame: 2-4 years
measure: • Correlation of individual tumour cytokeratins (eg. CK5 and CK17 expression) with chemotherapy response and resistance
timeFrame: 2-4 years
measure: Cell free circulating tumor (ct) DNA analysis (including KRAS mutational status)
timeFrame: 2-4 years
measure: Cluster Tendency analysis using artificial neural networks and radiomic methods combined
timeFrame: 2-4 years
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
state: Maryland
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
city: New Hyde Park
country: United States
facility: Northwell Health
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Vancouver
country: Canada
facility: BC Cancer Agency Vancouver
state: British Columbia
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre
state: Ontario
Study officials:
affiliation: Johns Hopkins University
name: Elizabeth Jaffee, MD
role: STUDY_CHAIR
affiliation: University Health Network, Toronto
name: Jennifer J Knox, MD
role: STUDY_CHAIR
References: